Shanxi Traditional Chinese Medical Hospital, Taiyuan, China.
Shanxi University of Chinese Medicine, Taiyuan, China.
PLoS One. 2024 Mar 28;19(3):e0298732. doi: 10.1371/journal.pone.0298732. eCollection 2024.
IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis worldwide and a leading cause of chronic kidney failure. There are currently no definitive therapeutic regimens to treat or prevent the progression of IgAN. However, biologic agents offer novel therapeutic approaches that target immunological mechanisms to slow or halt disease progression. The objective of this study is to evaluate the efficacy and safety of biologic agents in patients with IgA nephropathy.
We will systematically search PubMed, EMbase, Web of Science, Cochrane Library, and www.clinicaltrials.gov for randomized controlled trials of biologic agents for the treatment of IgA nephropathy. The search period will span from the establishment of each database until October 2023. The quality assessment of included studies will be performed individually using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), and meta-analysis will be conducted using Revman 5.4.1 software.
The results of this study will provide evidence-based medical evidence for the clinical application of biologic agents in patients with IgA nephropathy.
CRD42023400450.
IgA 肾病（IgAN）是全球最常见的原发性肾小球肾炎，也是慢性肾衰竭的主要原因。目前尚无明确的治疗方案可用于治疗或预防 IgAN 的进展。然而，生物制剂提供了针对免疫机制的新型治疗方法，以减缓或阻止疾病进展。本研究的目的是评估生物制剂在 IgA 肾病患者中的疗效和安全性。
我们将系统地检索 PubMed、EMbase、Web of Science、Cochrane 图书馆和 www.clinicaltrials.gov 中关于生物制剂治疗 IgA 肾病的随机对照试验。检索时间将从每个数据库的建立开始，一直持续到 2023 年 10 月。使用修订后的 Cochrane 随机对照试验偏倚风险工具（RoB 2）对纳入研究进行个体质量评估，并使用 RevMan 5.4.1 软件进行荟萃分析。
本研究的结果将为 IgA 肾病患者中生物制剂的临床应用提供循证医学证据。
PROSPERO 注册号：CRD42023400450。
